162 related articles for article (PubMed ID: 8864181)
1. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats.
Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G
Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
6. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
7. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
8. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices.
Gandhi H; Patel VB; Mistry N; Patni N; Nandania J; Balaraman R
Environ Toxicol Pharmacol; 2013 Nov; 36(3):787-95. PubMed ID: 23958971
[TBL] [Abstract][Full Text] [Related]
11. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of melatonin on adriamycin-induced acute cardiac injury.
Koçak G; Erbil KM; Ozdemir I; Aydemir S; Sunar B; Tuncel M; Atalay S
Can J Cardiol; 2003 Apr; 19(5):535-41. PubMed ID: 12717489
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187).
Samelis GF; Stathopoulos GP; Kotsarelis D; Dontas I; Frangia C; Karayannacos PE
Anticancer Res; 1998; 18(5A):3305-9. PubMed ID: 9858900
[TBL] [Abstract][Full Text] [Related]
14. Rat Model of Cardiotoxic Drug-Induced Cardiomyopathy.
Nakahara T; Tanimoto T; Petrov AD; Ishikawa K; Strauss HW; Narula J
Methods Mol Biol; 2018; 1816():221-232. PubMed ID: 29987823
[TBL] [Abstract][Full Text] [Related]
15. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis in young rats with adriamycin-induced cardiomyopathy--comparison with pirarubicin, a new anthracycline derivative.
Koh E; Ueda Y; Nakamura T; Kobayashi A; Katsuta S; Takahashi H
Pediatr Res; 2002 Feb; 51(2):256-9. PubMed ID: 11809923
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
18. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat.
Burke BE; Gambliel H; Olson RD; Bauer FK; Cusack BJ
Br J Pharmacol; 2000 Sep; 131(1):1-4. PubMed ID: 10960060
[TBL] [Abstract][Full Text] [Related]
19. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 4'-iodo-4'-deoxydoxorubicin-induced cardiotoxicity in two experimental rat models.
Podestà A; Della Torre P; Pinciroli G; Iatropoulos MJ; Brughera M; Mazué G
Toxicol Pathol; 1994; 22(1):68-71. PubMed ID: 8073224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
